Growth Hormone Disorders Completed Phase 3 Trials for Somapacitan (DB15093)

Also known as: Growth Hormone Disorder

IndicationStatusPhase
DBCOND0036845 (Growth Hormone Disorders)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03075644A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone DeficiencyTreatment
NCT02382939A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone DeficiencyTreatment
NCT02229851Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.Treatment